A Phase I, open label study of SIRPα antagonist (BI 770371) with or without ezabenlimab (PD-1 inhibitor) in patients with advanced solid tumors
AE, adverse event; DLT, dose-limiting toxicity; ECOG PS, Eastern Cooperative Oncology Group performance status; MTD, maximum tolerated dose; SIRPα, signal-regulatory protein alpha.